BLAINJECTIONINJECTABLE
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
TRUXIMA (rituximab-abbs) by Celltrion is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRUXIMA (rituximab-abbs) is a CD20-directed cytolytic monoclonal antibody approved by the FDA in November 2018 as a biosimilar to reference rituximab. It works by binding to CD20 antigen on B cells, leading to B-cell lysis and is indicated for the treatment of CD20-positive B-cell malignancies and autoimmune conditions. The product is manufactured by Celltrion and represents an important biosimilar option in the growing anti-CD20 therapeutic class.
$0.0BPart D
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Started Jul 2022
60 enrolled
Lymphoma, Large B-Cell, Diffuse (DLBCL)
Why This Matters for Your Career
Worked on TRUXIMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.